Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers looking at multiple sclerosis investigate using drugs normally prescribed for other diseases.

Affecting 1 in 1,000 people, multiple sclerosis (MS) is an autoimmune disease in which the body’s immune system attacks its own brain and spinal cord.

Professor Lars Fugger’s research at the Nuffield Department of Clinical Neurosciences has found that a drug used to treat hypertension also has some efficacy against neurodegeneration, which is part of MS.

I've seen over the years that there is light at the end of the tunnel, and that if you just push, you will make a difference. - Professor Lars Fugger

MS seems to share some factors with two different groups of diseases: those involving the immune system, such as rheumatoid arthritis, psoriasis and type 1 diabetes; and those involving neurodegenerative conditions of the brain, as in Parkinson’s disease and Alzheimer’s. Data sets relating to all these are being analysed for any patterns or commonalities which could help in identifying new therapeutic strategies against MS.

Read more on the Oxford Thinking website...

Similar stories

Attention and memory deficits persist for months after recovery from mild COVID

Researchers from Oxford’s Nuffield Department of Clinical Neurosciences and Department of Experimental Psychology have shown that people who have had COVID but don’t complain of long COVID symptoms in daily life nevertheless can show degraded attention and memory for up to six to nine months.

New Academic Visitor from Nigeria

Associate Professor of Radiology, Godwin Ogbole has arrived on a six-month visit to the Nuffield Department of Clinical Neurosciences, as part of the Africa Oxford Initiative.

New spinout company: Human-Centric Drug Discovery

Human-Centric Drug Discovery is a new Oxford University spinout company from Professor Zameel Cader's lab.

Funding received for research into Motor Neuron Disease

A £210,000 donation from the Alan Davidson Foundation has been made to our Department to advance our world-leading research into Motor Neuron Disease. The funding will support a project manager to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis.

Research finds drug may benefit some patients hospitalised with COVID-19 pneumonia

A proof-of-concept trial involving Oxford researchers has identified a drug that may benefit some patients hospitalised with COVID-19 pneumonia.

Protein test could lead to earlier and better diagnosis of Parkinson’s

Scientists have observed the clumping of alpha-synuclein in the cerebrospinal fluid taken from people with Parkinson's. The findings offer hope that a pioneering new clinical test could be developed to diagnose Parkinson's correctly in its early stages.